The CoE CIT established a new translation research laboratory in 2021. This lab is dedicated to building a research pipeline to improve the production and testing of novel cellular immunotherapy approaches for rapid translation into proof-of-concept clinical trials. Projects can enter the pipeline at any stage for progression into the Pilot Clinical Trial Development Program.
The CoE CIT Translation Laboratory, in partnership with Cell Therapies Pty Ltd, facilitates the progression of academic and industry led cell-based immunotherapy breakthroughs into the clinic by contributing preclinical research and GMP-compliant manufacturing expertise.
The CoE CIT Translation Laboratory can design and produce CARs (chimeric antigen receptors) with extensive expertise in the performing in vitro and in vivo quality control testing of CAR-T cell products and facilitating tech transfer to GMP manufacturing. The CoE CIT Translation Laboratory:
- expedites the bench to bedside transition of novel cellular immunotherapies
- supports important translational studies on patient samples derived from these first-in-human clinical trials
In addition, the CoE CIT Translation Laboratory can assist in the following:
- CAR (Chimeric Antigen Receptor) design
- CAR-T cell generation for preclinical research
- Human and murine in vitro assays to assess CAR-T cell functionality
- Murine in vivo models to assess CAR-T cell efficacy
- GMP CAR-T cell manufacture
For more information on the CoE CIT Translational Laboratory, contact